Search Results - "Hawkes, Eliza Anne"

Frontline treatment of follicular lymphoma with atezolizumab and obinutuzumab, with and without radiotherapy (The FLUORO study) by Hawkes, Eliza Anne, Manos, Kate, Khor, Richard, Douglas, Genevieve, Lee, Sze Ting, Lee, Denise, Campbell, Belinda, Grobler, Anneke, Gilbertson, Michael, Palmer, Jodie, Chong, Geoff

“…TPS7587 Background: Follicular lymphoma (FL) is the commonest indolent lymphoma, comprising 20% of non-Hodgkin Lymphoma, with approximately 80% of patients…”
Get full text

Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study by Hawkes, Eliza Anne, Lee, Sze Ting, Chong, Geoff, Gilbertson, Michael, Grigg, Andrew, Churilov, Leonid, Fancourt, Tineke, Keane, Colm, Ritchie, David, Koldej, Rachel, Agarwal, Rishu, Manos, Kate, Smith, Charmaine, Houdyk, Kristen, Hawking, Joanne, Barraclough, Allison

“…Abstract only 7560 Background: Standard of care immunochemotherapy in front-line (1L) follicular lymphoma (FL) is highly efficacious but not without…”
Get full text

Ability of routine blood tests (RBTs) in asymptomatic patients (pts) with indolent non-Hodgkin lymphoma (iNHL) to detect relapse or clinically significant disease progression by Piercey, Oliver, Loh, Zoe, Chan, Joanna, Chong, Geoffrey, Grigg, Andrew, Cheema, Steven, Cushion, Tania, Gill, Gurjot, Whybird, Matthew, Hawkes, Eliza Anne

“…Abstract only e19027 Background: Pts with iNHL undergo active surveillance to detect disease relapse or progression. International guidelines recommend regular…”
Get full text

Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study by Hawkes, Eliza Anne, Manos, Kate, Chong, Geoffrey, Palmer, Jodie, MacManus, Michael Patrick, Keane, Colm, Scott, Andrew Mark, Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison Anne, Lee, Sze Ting, Lin, Wendi, Koldej, Rachel, Khor, Richard

“…Abstract only TPS8075 Background: Most DLBCL & FL responds well to first line treatment, yet relapsed disease outcomes are poor. PD1/PDL1 inhibitors yield high…”
Get full text

Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL) by Barton, Sarah Rachel, Hawkes, Eliza Anne, Cunningham, David, Peckitt, Clare, Chua, Sue, Wotherspoon, Andrew, Attygalle, Ayoma, Horwich, Alan, Dearden, Claire E., Potter, Mike, Chau, Ian

“…Abstract only e19543 Background: Patients with DLBCL who relapse after 1st line therapy have poor prognosis. Although there is limited evidence for benefit of…”
Get full text

Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data by Sathyanarayanan, Sriram, Ayers, Mark, Cunningham, David, Tejpar, Sabine, Tabernero, Josep, Hawkes, Eliza Anne, Kim, Tae Won, Kim, Tae-You, Kim, Sun Young, Loboda, Andrey, Nebozhyn, Michael, Mogg, Robin, Naumov, George, Bloecher, Andrew, Valentine, Erin, Brown, Holly M., Watkins, David J., Mauro, David J.

“…Abstract only 3587 Background: KRAS mutated metastatic colorectal cancer (mCRC) is inherently resistant to EGFR targeted therapy and carries an inferior…”
Get full text